Zealic Health and Coriqa Clinical form partnership to make trials more proactive

Zealic Health and Coriqa Clinical announced a strategic partnership on September 29, 2026, to help sponsors, CROs and sites spot clinical trial risks earlier and intervene during execution. The companies say the goal is to reduce rework, delays and compliance issues by shifting trial oversight from reactive review to real-time action.

Why it matters: - Clinical trials can lose time and quality when problems are found after execution instead of during it. - Earlier intervention can reduce protocol deviations, data-quality issues, rework and compliance risk. - The partnership aims to help sponsors, CROs, sites and study teams avoid delays that can affect data cuts, evaluations, database lock and regulatory submissions.

What happened: - Zealic Health, a life sciences technology company, and Coriqa Clinical, a Holly Springs, N.C.-based clinical operations consultancy, announced a strategic partnership on September 29, 2026. - The companies say the partnership is designed to move clinical trial execution from reactive oversight to proactive intervention and prevention. - The partnership builds on an established working relationship between the founders and draws on decades of life sciences experience.

The details: - Zealic Health and Coriqa Clinical are combining strengths across technology, clinical operations, engineering, science and real-world trial execution. - The partnership is centered on identifying risks while work is happening, detecting errors as they are introduced and intervening before issues become deviations. - The companies say the effort is meant to close two persistent gaps in clinical research: the gap between new technology and how it is actually used, and the gap between protocol requirements and day-to-day execution. - Zealic Health says sophisticated technology is easier to apply when operational realities are built into the process. - Zealic Health CEO and Founder Chuck Piccirillo said the companies know the industry, know each other and are bringing techniques, methodologies and technologies proven in other industries into life sciences. - Coriqa Clinical CEO and Principal Consultant Wendy Tomlinson said clinical trials need better ways to turn information into action while work is happening. - Coriqa Clinical’s role is to bring operational reality into the equation so technology supports trial teams and helps them get it right the first time, Tomlinson said. - Zealic Health’s clinical research solution, SiteOS, works alongside site execution to identify human and operational errors while work is happening. - Zealic Health says SiteOS is designed to help prevent those errors from becoming protocol deviations, rework, delays, data-quality issues or compliance risk. - Coriqa Clinical says its consulting work helps sponsors, CROs, sites and site networks improve trial planning and execution. - The firm says it focuses on identifying execution gaps, reducing friction and translating strategy into practical, sustainable improvements. - The companies included their websites for more information: Zealic Health and Coriqa Clinical. - Zealic Health also provided a LinkedIn page: Zealic Health on LinkedIn.

Between the lines: - The announcement signals a push to use technology not just for monitoring, but for active prevention at the point of execution. - The partnership also suggests the companies see clinical trial quality problems as an operations challenge as much as a software challenge. - The message is that better trial outcomes may come from combining real-time intelligence with hands-on operational expertise.

What's next: - Zealic Health and Coriqa Clinical are positioning the partnership to improve execution quality and reduce unnecessary delay. - The companies say the longer-term goal is a more reliable path to bringing new therapies to patients. - The announcement does not include a timeline for new product launches, pilot programs or commercial rollout.

The bottom line: - Zealic Health and Coriqa Clinical are betting that clinical trials can run better when risks are caught during execution, not after the fact.